Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Purchased by Woodline Partners LP

Woodline Partners LP raised its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 110.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,410,520 shares of the company's stock after purchasing an additional 739,713 shares during the quarter. Woodline Partners LP owned 2.61% of Fulcrum Therapeutics worth $6,629,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. MetLife Investment Management LLC lifted its holdings in Fulcrum Therapeutics by 145.8% during the fourth quarter. MetLife Investment Management LLC now owns 40,107 shares of the company's stock valued at $189,000 after purchasing an additional 23,792 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Fulcrum Therapeutics by 5.9% in the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company's stock worth $567,000 after buying an additional 6,770 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Fulcrum Therapeutics by 25.1% in the fourth quarter. Northern Trust Corp now owns 710,321 shares of the company's stock worth $3,339,000 after buying an additional 142,578 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Fulcrum Therapeutics by 34.4% in the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company's stock worth $161,000 after buying an additional 8,761 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Fulcrum Therapeutics by 46.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 52,368 shares of the company's stock worth $247,000 after buying an additional 16,656 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Trading Up 6.4%

FULC stock traded up $0.44 during midday trading on Thursday, reaching $7.34. The stock had a trading volume of 287,121 shares, compared to its average volume of 967,775. The company's fifty day simple moving average is $4.24 and its 200 day simple moving average is $3.97. The company has a market cap of $396.21 million, a price-to-earnings ratio of -23.56 and a beta of 2.29. Fulcrum Therapeutics, Inc. has a 52-week low of $2.32 and a 52-week high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. Sell-side analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. HC Wainwright reissued a "neutral" rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. Leerink Partners upgraded shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $4.00 to $12.00 in a report on Friday, May 23rd. Piper Sandler reaffirmed an "overweight" rating and issued a $9.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday. Leerink Partnrs raised shares of Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Friday, May 23rd. Finally, Cantor Fitzgerald upgraded shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price target on the stock in a report on Thursday, May 15th. One analyst has rated the stock with a sell rating, three have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $6.29.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.